Table 3.

Data from six prospective randomized trials on changes in renal function among patients with ARASa

Reference Treatment Group Mean Follow-up Period (mo) Mean Initial Plasma Creatinine Concentration (μM) Mean Change from Baseline in Plasma Creatinine Concentration (μM)
aPTRA, percutaneous transluminal renal artery angioplasty.
bIn this trial, reported in abstract form, no data were available for patients assigned to the surgical revascularization group.
Weibull et al. (3) Surgery, (n = 29) 24 115 2
PTRA (n = 29) 97 2
van de Ven et al. (8) PTRA + stent (n = 42) 6 150 24
PTRA (n = 42) 133 24
Webster et al. (6)
unilateral stenosis Medication (n = 13) 3 to 54 168 0
Intervention (n = 14) 138 8
bilateral stenoses Medication (n = 12) 148 4
Intervention (n = 16) 182 1
Plouin et al. (7) Medication (n = 26) 6 105 -9
PTRA (n = 23) 96 +1
van Jaarsveld et al. (9) Medication (n = 50) 12 115 -9
PTRA (n = 56) 106 0
Pohl et al. (28)b Medication (n = 40) 6.7 168 9